Citadel Advisors’s Travere Therapeutics TVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.81M Buy
128,364
+108,029
+531% +$3.23M ﹤0.01% 4804
2025
Q4
$777K Sell
20,335
-39,418
-66% -$1.28M ﹤0.01% 7978
2025
Q3
$1.43M Sell
59,753
-651,504
-92% -$12.2M ﹤0.01% 6770
2025
Q2
$10.5M Buy
711,257
+186,922
+36% +$3.1M ﹤0.01% 2950
2025
Q1
$9.4M Sell
524,335
-54,801
-9% -$1.11M ﹤0.01% 2939
2024
Q4
$10.1M Sell
579,136
-195,953
-25% -$3.47M ﹤0.01% 2975
2024
Q3
$10.8M Buy
775,089
+134,780
+21% +$1.4M ﹤0.01% 2779
2024
Q2
$5.26M Buy
640,309
+485,681
+314% +$3.27M ﹤0.01% 3675
2024
Q1
$1.19M Sell
154,628
-84,172
-35% -$710K ﹤0.01% 6566
2023
Q4
$2.15M Sell
238,800
-303,762
-56% -$2.21M ﹤0.01% 5226
2023
Q3
$4.85M Buy
542,562
+509,037
+1,518% +$7.18M ﹤0.01% 3692
2023
Q2
$515K Sell
33,525
-876,474
-96% -$15.9M ﹤0.01% 7876
2023
Q1
$20.5M Sell
909,999
-44,095
-5% -$937K ﹤0.01% 1890
2022
Q4
$20.1M Sell
954,094
-145,596
-13% -$3.09M ﹤0.01% 1964
2022
Q3
$27.1M Sell
1,099,690
-206,346
-16% -$5.33M 0.01% 1582
2022
Q2
$31.6M Sell
1,306,036
-132,742
-9% -$3.34M 0.01% 1425
2022
Q1
$37.1M Buy
1,438,778
+612,402
+74% +$16.3M 0.01% 1354
2021
Q4
$25.7M Buy
826,376
+24,006
+3% +$676K 0.01% 1751
2021
Q3
$19.5M Buy
802,370
+777,966
+3,188% +$14.3M ﹤0.01% 2032
2021
Q2
$356K Buy
24,404
+5,201
+27% +$103K ﹤0.01% 10858
2021
Q1
$480K Sell
19,203
-945,325
-98% -$26.1M ﹤0.01% 9764
2020
Q4
$26.3M Buy
964,528
+336,048
+53% +$7.85M 0.01% 1528
2020
Q3
$11.6M Buy
628,480
+275,585
+78% +$5.36M ﹤0.01% 2113
2020
Q2
$7.2M Buy
352,895
+238,339
+208% +$3.79M ﹤0.01% 2604
2020
Q1
$1.67M Buy
+114,556
New +$1.72M ﹤0.01% 4430
2019
Q4
Sell
-144,730
Closed -$1.68M 9789
2019
Q3
$1.68M Sell
144,730
-204,167
-59% -$3.37M ﹤0.01% 4775
2019
Q2
$7.01M Buy
348,897
+250,430
+254% +$4.94M ﹤0.01% 2624
2019
Q1
$2.23M Buy
98,467
+25,789
+35% +$570K ﹤0.01% 4287
2018
Q4
$1.65M Buy
+72,678
New +$1.81M ﹤0.01% 4464
2018
Q3
Sell
-50,851
Closed -$1.45M 9701
2018
Q2
$1.39M Sell
50,851
-22,518
-31% -$600K ﹤0.01% 4672
2018
Q1
$1.64M Sell
73,369
-284,914
-80% -$6.79M ﹤0.01% 4038
2017
Q4
$7.55M Sell
358,283
-52,554
-13% -$1.2M ﹤0.01% 2008
2017
Q3
$10.2M Sell
410,837
-196,935
-32% -$4.34M 0.01% 1578
2017
Q2
$11.8M Sell
607,772
-201,119
-25% -$3.65M 0.01% 1338
2017
Q1
$14.9M Buy
808,891
+535,720
+196% +$10.5M 0.01% 1158
2016
Q4
$5.17M Buy
273,171
+204,270
+296% +$4.18M 0.01% 1968
2016
Q3
$1.54M Sell
68,901
-513,924
-88% -$9.78M ﹤0.01% 3274
2016
Q2
$10.4M Buy
582,825
+420,273
+259% +$6.8M 0.01% 1219
2016
Q1
$2.22M Buy
162,552
+12,637
+8% +$192K ﹤0.01% 2538
2015
Q4
$2.89M Buy
149,915
+18,476
+14% +$369K ﹤0.01% 2366
2015
Q3
$2.66M Buy
131,439
+17,758
+16% +$526K ﹤0.01% 2604
2015
Q2
$3.77M Buy
113,681
+70,201
+161% +$1.92M ﹤0.01% 2332
2015
Q1
$1.04M Buy
43,480
+21,055
+94% +$321K ﹤0.01% 3871
2014
Q4
$274K Buy
22,425
+20,348
+980% +$211K ﹤0.01% 5571
2014
Q3
$19K Sell
2,077
-14,136
-87% -$166K ﹤0.01% 7488
2014
Q2
$190K Sell
16,213
-10,505
-39% -$142K ﹤0.01% 5624
2014
Q1
$568K Buy
+26,718
New +$411K ﹤0.01% 4173

Other funds holding TVTX

Citadel Advisors's TVTX Position: Q1 2026 in Review

Citadel Advisors increased its Travere Therapeutics (TVTX) stake by 531% in Q1 2026, buying an estimated $3.23M and bringing the position to 128,364 shares worth $3.81M. The position accounts for ﹤0.01% of the portfolio, ranked #4804.

Citadel Advisors first reported a position in TVTX in Q1 2014 and has held it in 47 quarters since. The position peaked at $37.1M in Q1 2022. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Citadel Advisors held 128,364 shares of Travere Therapeutics worth $3.81M as of Q1 2026.
  • Citadel Advisors bought 108,029 Travere Therapeutics shares in Q1 2026, an estimated $3.23M.
  • Travere Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4804 holding.
  • Citadel Advisors first reported a position in Travere Therapeutics in Q1 2014 and has held it in 47 quarters since.
  • Citadel Advisors's Travere Therapeutics position peaked at $37.1M in Q1 2022.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.